These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
453 related articles for article (PubMed ID: 27748762)
1. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762 [TBL] [Abstract][Full Text] [Related]
2. The Hedgehog signaling pathway promotes chemotherapy resistance via multidrug resistance protein 1 in ovarian cancer. Zhang H; Hu L; Cheng M; Wang Q; Hu X; Chen Q Oncol Rep; 2020 Dec; 44(6):2610-2620. PubMed ID: 33125122 [TBL] [Abstract][Full Text] [Related]
3. NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivo. Jalili A; Mertz KD; Romanov J; Wagner C; Kalthoff F; Stuetz A; Pathria G; Gschaider M; Stingl G; Wagner SN PLoS One; 2013; 8(7):e69064. PubMed ID: 23935925 [TBL] [Abstract][Full Text] [Related]
4. The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Mazumdar T; DeVecchio J; Agyeman A; Shi T; Houghton JA Oncotarget; 2011 Aug; 2(8):638-45. PubMed ID: 21860067 [TBL] [Abstract][Full Text] [Related]
5. Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. Spender LC; Ferguson GJ; Liu S; Cui C; Girotti MR; Sibbet G; Higgs EB; Shuttleworth MK; Hamilton T; Lorigan P; Weller M; Vincent DF; Sansom OJ; Frame M; Dijke PT; Marais R; Inman GJ Oncotarget; 2016 Dec; 7(50):81995-82012. PubMed ID: 27835901 [TBL] [Abstract][Full Text] [Related]
6. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149 [TBL] [Abstract][Full Text] [Related]
7. A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. Sinnberg T; Makino E; Krueger MA; Velic A; Macek B; Rothbauer U; Groll N; Pötz O; Czemmel S; Niessner H; Meier F; Ikenberg K; Garbe C; Schittek B EBioMedicine; 2016 Jun; 8():132-149. PubMed ID: 27428425 [TBL] [Abstract][Full Text] [Related]
8. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells. Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432 [TBL] [Abstract][Full Text] [Related]
9. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374 [TBL] [Abstract][Full Text] [Related]
10. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016 [TBL] [Abstract][Full Text] [Related]
11. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Sabbatino F; Wang Y; Wang X; Flaherty KT; Yu L; Pepin D; Scognamiglio G; Pepe S; Kirkwood JM; Cooper ZA; Frederick DT; Wargo JA; Ferrone S; Ferrone CR Oncotarget; 2014 Apr; 5(7):1926-41. PubMed ID: 24732172 [TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
14. CDK7 inhibition suppresses aberrant hedgehog pathway and overcomes resistance to smoothened antagonists. Liu F; Jiang W; Sui Y; Meng W; Hou L; Li T; Li M; Zhang L; Mo J; Wang J; Zhao Y; Zhang L; Ma J; Tang Y Proc Natl Acad Sci U S A; 2019 Jun; 116(26):12986-12995. PubMed ID: 31182587 [TBL] [Abstract][Full Text] [Related]
15. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. Qin Y; Roszik J; Chattopadhyay C; Hashimoto Y; Liu C; Cooper ZA; Wargo JA; Hwu P; Ekmekcioglu S; Grimm EA Mol Cancer Ther; 2016 Oct; 15(10):2442-2454. PubMed ID: 27458138 [TBL] [Abstract][Full Text] [Related]
16. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642 [TBL] [Abstract][Full Text] [Related]
17. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal. Lu Y; Zhao Y; Liu P; Xu X Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37643458 [TBL] [Abstract][Full Text] [Related]
18. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Girotti MR; Pedersen M; Sanchez-Laorden B; Viros A; Turajlic S; Niculescu-Duvaz D; Zambon A; Sinclair J; Hayes A; Gore M; Lorigan P; Springer C; Larkin J; Jorgensen C; Marais R Cancer Discov; 2013 Feb; 3(2):158-67. PubMed ID: 23242808 [TBL] [Abstract][Full Text] [Related]
19. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Shi H; Kong X; Ribas A; Lo RS Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746 [TBL] [Abstract][Full Text] [Related]
20. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]